Neurotrope Bioscience, Inc.
Get Full AccessDescription
- Caring Deeply. Changing Lives. We measure success by our impact on patients we serve. Neurotrope BioScience, (OTCQB:NTRPD), formed in 2012, is at the forefront of the biotech industry and is focused on developing novel therapies with Bryostatin 1 for the treatment of neurodegenerative diseases and developmental disorders, initially focused on Alzheimers. We have a pipeline that includes various treatment approaches with Bryostatin 1 for serious and difficult-to-treat Orphan diseases, including Fragile X Syndrome (FXS) and Niemann-Pick Type C (NPC). Multi Modal Efficacy Bryostatin-1 activates Synaptic Growth Factors BDNF, NGF, IGF, others. It also activates all amyloid-β Degrading Enzymes (ECE, Neprilysin, IDE). Bryostatin also activates α-secretase, which reduces formation of neurotoxic amyloid-β formed by γ-secretase and BACE. ApoE3 induces PKCϵ; by activating PKCϵ, so there is an increase in BDNF expression. Bryostatin blocks ApoE4's reduction of BDNF via HDAC inhibition. Bryostatin normalizes GSK3-β, thereby inhibiting pathological Tau protein transformation into neurofibrillary tangles (NFTs). Alzheimers disease Bryostatin is currently being tested in a 148 moderate to severe Alzheimer's disease patient population across 26 sites in the U.S. First patients dosed January 2016 and now fully enrolled. Primary efficacy endpoint based on Severe Impairment Battery Scale (SIB). Entry criteria based on the MMSE score. Top line data expected in April 2017. Fragile X Syndrome (FXS) is a devastating genetic disorder that causes developmental delays in children (135,000 U.S.), including developmental delays, intellectual and learning disabilities, anxiety, and autism spectrum disorders. In multiple FXS animal models it was shown that Bryostatin 1 improved memory and learning and behavior, the latter independently with the FRAXA Research Foundation. We plan to institute a Phase 2 clinical trial in FXS patients early next year.
-
Headquarters:205 East 42nd Street , New York, New York, United States
More -
Phone Number: +1 973-242-0005
-
Website: https://www.neurotropebioscience.com
-
Employees:4
-
Revenue:$1 - 10M
-
Legal Name:Neurotrope Bioscience, Inc.
-
Neurotrope Bioscience, Inc.'s Social Media
-
Is this data correct?
-
| NAICS Code: 325412 |
Show More
Sell more in less time!
Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!
Frequently Asked Questions regarding Neurotrope Bioscience, Inc.
-
Where are Neurotrope Bioscience, Inc.'s Headquarters?
Neurotrope Bioscience, Inc.'s Headquarters are in 205 East 42nd Street ,New York,New York,United States
-
What is Neurotrope Bioscience, Inc.'s phone number?
Neurotrope Bioscience, Inc.'s phone number is +1 973-242-0005
-
What is Neurotrope Bioscience, Inc.'s official website?
Neurotrope Bioscience, Inc.'s official website is https://www.neurotropebioscience.com
-
What is Neurotrope Bioscience, Inc.'s Revenue?
Neurotrope Bioscience, Inc.'s revenue is $1 - 10M
-
What is Neurotrope Bioscience, Inc.'s NAICS code?
Neurotrope Bioscience, Inc.'s NAICS code is 325412
-
How many employees are working in Neurotrope Bioscience, Inc.
Neurotrope Bioscience, Inc. has 4 employees
-
What is Neurotrope Bioscience, Inc.'s Industry?
Neurotrope Bioscience, Inc. is in the industry of Pharmaceuticals
-
Who is Neurotrope Bioscience, Inc.'s Chief Financial Officer?
Neurotrope Bioscience, Inc.'s Chief Financial Officer is Robert Weinstein